Q&A With Sophie Megnien From Genfit: Work Progressing On New Nonalcoholic Steatohepatitis Treatment

Video

While there are currently no approved treatments for nonalcoholic steatoheptitis there are medications working their way through the approval process including at least a few in phase III studies.

While there are currently no approved treatments for nonalcoholic steatoheptitis there are medications working their way through the approval process including at least a few in phase III studies.

One of the companies working on bringing this new treatment to the market is Genfit whose Chief Medical Officer Sophie Megnien talked about what this could mean for patients during the annual Liver meeting in San Francisco.

Related Videos
Andrew Talal, MD | Credit: University at Buffalo
Andrew Talal, MD | Credit: University at Buffalo
Megan Rose Curtis, MD | Credit: Megan Rose Curtis on LinkedIn
Wei Zhang, MD, PhD | Credit: Mass General Brigham
Women at 50% Greater Risk Progressing from Alcoholic Hepatitis Cirrhosis than Men
Nancy Reau, MD: Larsucosterol for Alcohol-Associated Hepatitis
Taha Qazi, MD: Evolving Bariatric Surgery Value in GI
Taha Qazi, MD: Addressing Smoking Cessation in the GI Office
© 2024 MJH Life Sciences

All rights reserved.